Palbociclib

Specifications

571190-30-2CAS Number

810-186-2EC Number

6-acetyl-8-cyclopentyl-5-methyl-2-[(5-piperazin-1-yl-2-pyridinyl)amino]pyrido[2,3-d]pyrimidin-7-oneIUPAC Name

C24H29N7O2Chemical Formula

447.5 g/molMolecular Weight

Palbociclib; 571190-30-2; Ibrance; PD-0332991; PD0332991; PD 0332991; 6-acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one; G9ZF61LE7G; PD 332991; 6-Acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-ylpyridin-2-ylamino)-8H-pyrido(2,3-d)pyrimidin-7-one; 6-Acetyl-8-cyclopentyl-5-methyl-2-[[5-(piperazin-1-yl)pyridin-2-yl]amino]-8H-pyrido[2,3-d]pyrimidin-7-one; CHEBI:85993; DTXSID40972590; 6-acetyl-8-cyclopentyl-5-methyl-2-{[5-(piperazin-1-yl)pyridin-2-yl]amino}pyrido[2,3-d]pyrimidin-7(8H)-one; Pyrido(2,3-d)pyrimidin-7(8H)-one, 6-acetyl-8-cyclopentyl-5-methyl-2-((5-(1-piperazinyl)-2-pyridinyl)amino)-; Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-acetyl-8-cyclopentyl-5-methyl-2-[[5-(1-piperazinyl)-2-pyridinyl]amino]-; palbociclibum; 6-ACETYL-8-CYCLOPENTYL-5-METHYL-2-((5-(PIPERAZIN-1-YL)PYRIDIN-2-YL)AMINO)-8H-PYRIDO(2,3-D)PYRIMIDIN-7-ONE; 6-acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)pyrido(2,3-d)pyrimidin-7(8H)-one; 6-acetyl-8-cyclopentyl-5-methyl-2-((5-piperazin-1-ylpyridin-2-yl)amino)pyrido(6,5-d)pyrimidin-7-one; 6-acetyl-8-cyclopentyl-5-methyl-2-[(5-piperazin-1-ylpyridin-2-yl)amino]pyrido[6,5-d]pyrimidin-7-one; RefChem:6097; DTXCID80207212; L01XE33; PD 991; UNII-G9ZF61LE7G; MFCD11840850; 6-ACETYL-8-CYCLOPENTYL-5-METHYL-2-[(5-PIPERAZIN-1-YLPYRIDIN-2-YL)AMINO]PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE; Palbociclib(PD0332991); C24H29N7O2; LQQ; Palbociclib free base; 2euf; Palbociclib [USAN]; PD-332991; 571190-30-2 (free base); Palbociclib [USAN:INN]; Palbociclib?; Palbociclib base; 6-Acetyl-8-cyclopentyl-5-methyl-2-[[5-(1-piperazinyl)-2-pyridinyl]amino]pyrido[2,3-d]pyrimidin-7(8H)-one; 6-Acetyl-8-cyclopentyl-5-methyl-2-{[5-(1-piperazinyl)-2-pyridinyl]amino}pyrido[2,3-d]pyrimidin-7(8H)-one; Ibrance (TN); Kinome_3823; Kinome_3824; Palbociclib (Standard); PALBOCICLIB [MI]; 6-acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-8h-pyrido[2,3-d]pyrimidin-7-one hydrochloride; PALBOCICLIB [INN]; PALBOCICLIB [JAN]; Palbociclib (JAN/USAN); PFE-PKIS 32; PFE-PKIS_32; PALBOCICLIB [WHO-DD]; 6-acetyl-8-cyclopentyl-5-methyl-2-[(5-piperazin-1-ylpyridin-2-yl)amino]pyrido[2,3-d]pyrimidin-7-one; 6-acetyl-8-cyclopentyl-5-methyl-2-{[5-(piperazin-1-yl)pyridin-2-yl]amino}-7H,8H-pyrido[2,3-d]pyrimidin-7-one; SCHEMBL462630; BDBM6309; CHEMBL189963; GTPL7380; orb1307454; Palbociclib - Bio-X trade mark; SCHEMBL29362383; SCHEMBL29379411; SCHEMBL30584526; EX-A408; PALBOCICLIB [ORANGE BOOK]; AHJRHEGDXFFMBM-UHFFFAOYSA-N; GLXC-90113; HMS3265M09; HMS3265M10; HMS3265N09; HMS3265N10; HMS3744G13; HMS5087D18; EBC-17116; HY-50767R; NSC758247; NSC772256; NSC800815; s4482; AKOS022205241; DB09073; FA65120; NSC-758247; NSC-772256; NSC-800815; SB40426; SDCCGSBI-0646936.P001; Pyrido-[2,3-d]-pyrimidin-7-one 43; NCGC00263129-01; NCGC00263129-08; NCGC00263129-21; NCGC00263129-22; NCGC00263129-26; 6-acetyl-8-cyclopentyl-5-methyl-2-[(5-piperazin-1-yl-2-pyridyl)amino]pyrido[2,3-d]pyrimidin-7-one; AC-25485; AS-17016; BP-43645; BP-44037; BP166224; HY-50767; SY026143; 571190-30-2(DMSO); NS00069617; D10372; EN300-18531248; F794410; P014442; PD 0332991,PD0332991; BRD-K51313569-001-01-1; BRD-K51313569-001-07-8; BRD-K51313569-003-03-3; Q15269707; Z2216894329; PALBOCICLIBPD-0332991PD0332991IBRANCECS-0019A-1030; 6-acetyl-8-cyclopentyl-5-methyl-2-(5-(piperazin-1-yl)pyridin-2-ylamino)pyrido[2,3-d]pyrimidin-7(8H)-one; 6-Acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-8H-pyrido[2,3-d]pyrimidin-7-one; 6-Acetyl-8-cyclopentyl-5-methyl-2-[[5-(1-piperazinyl)-2-pyridyl]amino]pyrido[2,3-d]pyrimidin-7(8H)-one; 6-Acetyl-8-cyclopentyl-5-methyl-2-[[5-(piperazin-1-yl)-pyridin-2-yl]amino]-8H-pyrido[2,3-d]pyrimidin-7-one; 8-cyclopentyl-6-acetyl-5-methyl-2-{[5-(piperazin-1-yl)pyridin-2-yl]amino}-7H,8H-pyrido[2,3-d]pyrimidin-7-oneSynonyms